Chief, Division of Surgical Oncology
The University of Texas at Austin Dell Medical School
The University of Texas at Austin Dell Medical School
R Y Declan Fleming, MD, FACS is the Chief of the Division of Surgical Oncology in the Department of Surgery and Perioperative Care of the Dell Medical School at the University of Texas at Austin. He also serves as the Associate Director for Surgical Services for the LIVESTRONG Cancer Institutes. He leads the clinical Surgical Oncology program as well as research projects focusing of frailty and fitness for complex surgery as an adjunct to Enhanced Surgical Recovery Programs. His clinical interests focus on treatment of patients with GI malignancies and Melanoma.
Dr. Fleming earned his MD from the University of Texas Medical Branch (UTMB) in Galveston, Texas where he went on to train as a resident in General Surgery. During his residency, he completed a research fellowship in Burns, Trauma, and Critical Care at the Galveston Shriners’ Burns Institute. He then undertook a three-year fellowship in Surgical Oncology at the M D Anderson Cancer Center in Houston, Texas, where he served as the Chief Fellow and earned the Marvin M. Rhomsdahl Clinical Excellence Award. Following his fellowship, Dr. Fleming became the inaugural Chief of Surgical Oncology at UTMB, but left to begin a private practice in Austin, Texas. While in Austin, he has served as President of the Travis County Medical Society, Associate Dean for Clinical Affairs for the Austin Regional Campus of UTMB, and as Chair of the Committee on Cancer for the Texas Medical Association. He left private practice in 2017 to re-enter academic medicine becoming the inaugural Chief of the Division of Surgical Oncology at Dell Medical School.
He is a member of numerous Medical Specialty Societies including Alpha Omega Alpha, the American College of Surgeons, the Society of Surgical Oncology, the Society for Surgery of the Alimentary Tract, the Americas Hepatico-Pancreatico-Biliary Association, and the North American Neuroendocrine Tumor Society.
Influence of Frailty and Prehabilitation on Outcomes in Cancer Surgery
Friday, September 16, 2022
10:30 AM – 11:30 AM East Coast USA Time
Disclosure(s): Alafair Biosciences: Stockholder (Ongoing)